CN101365808A - 用于评估hiv病毒适应度的方法、质粒载体和引物 - Google Patents
用于评估hiv病毒适应度的方法、质粒载体和引物 Download PDFInfo
- Publication number
- CN101365808A CN101365808A CNA2006800519873A CN200680051987A CN101365808A CN 101365808 A CN101365808 A CN 101365808A CN A2006800519873 A CNA2006800519873 A CN A2006800519873A CN 200680051987 A CN200680051987 A CN 200680051987A CN 101365808 A CN101365808 A CN 101365808A
- Authority
- CN
- China
- Prior art keywords
- labelization
- hiv
- virus
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 104
- 239000013600 plasmid vector Substances 0.000 title claims abstract description 36
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 269
- 108091093088 Amplicon Proteins 0.000 claims abstract description 94
- 239000000523 sample Substances 0.000 claims abstract description 61
- 230000003362 replicative effect Effects 0.000 claims abstract description 8
- 230000003321 amplification Effects 0.000 claims description 143
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 143
- 241000700605 Viruses Species 0.000 claims description 140
- 108020004414 DNA Proteins 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 238000003752 polymerase chain reaction Methods 0.000 claims description 71
- 230000037432 silent mutation Effects 0.000 claims description 61
- 239000013598 vector Substances 0.000 claims description 57
- 230000008521 reorganization Effects 0.000 claims description 54
- 239000013612 plasmid Substances 0.000 claims description 52
- 108700004025 env Genes Proteins 0.000 claims description 46
- 101150030339 env gene Proteins 0.000 claims description 46
- 230000001524 infective effect Effects 0.000 claims description 45
- 238000012217 deletion Methods 0.000 claims description 42
- 230000037430 deletion Effects 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 42
- 108091034117 Oligonucleotide Proteins 0.000 claims description 28
- 230000008859 change Effects 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 230000010076 replication Effects 0.000 claims description 27
- 108700004029 pol Genes Proteins 0.000 claims description 26
- 101150088264 pol gene Proteins 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 22
- 230000002103 transcriptional effect Effects 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 108700004026 gag Genes Proteins 0.000 claims description 17
- 101150098622 gag gene Proteins 0.000 claims description 16
- 230000008676 import Effects 0.000 claims description 14
- 108091026890 Coding region Proteins 0.000 claims description 11
- 238000007834 ligase chain reaction Methods 0.000 claims description 11
- 238000004113 cell culture Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 101800003160 Protease p15 Proteins 0.000 claims description 8
- 241000239226 Scorpiones Species 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 6
- 108010002459 HIV Integrase Proteins 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000005096 rolling process Methods 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 abstract description 49
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 24
- 230000012010 growth Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 7
- 238000011156 evaluation Methods 0.000 abstract description 3
- 238000003556 assay Methods 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000007877 drug screening Methods 0.000 abstract description 2
- 230000002974 pharmacogenomic effect Effects 0.000 abstract description 2
- 241001068263 Replication competent viruses Species 0.000 abstract 1
- 239000000758 substrate Substances 0.000 description 147
- 210000004027 cell Anatomy 0.000 description 44
- 238000004458 analytical method Methods 0.000 description 42
- 238000005336 cracking Methods 0.000 description 41
- 230000003197 catalytic effect Effects 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 108020004705 Codon Proteins 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 23
- 238000012544 monitoring process Methods 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 238000005516 engineering process Methods 0.000 description 21
- 230000001566 pro-viral effect Effects 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 102100034349 Integrase Human genes 0.000 description 16
- 238000013461 design Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 108700039887 Essential Genes Proteins 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 10
- 101710149951 Protein Tat Proteins 0.000 description 10
- 239000005547 deoxyribonucleotide Substances 0.000 description 10
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 206010059866 Drug resistance Diseases 0.000 description 9
- 108020000999 Viral RNA Proteins 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- 230000010534 mechanism of action Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 238000011225 antiretroviral therapy Methods 0.000 description 8
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 6
- 108010061833 Integrases Proteins 0.000 description 6
- 101150104269 RT gene Proteins 0.000 description 6
- -1 SJ-1366 Chemical compound 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical group O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 5
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical group C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 206010015856 Extrasystoles Diseases 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 108700004028 nef Genes Proteins 0.000 description 3
- 101150023385 nef gene Proteins 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 101150038105 pr gene Proteins 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 238000010223 real-time analysis Methods 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- 102100034866 Kallikrein-6 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- ZILOOGIOHVCEKS-HZFUHODCSA-N Telinavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 ZILOOGIOHVCEKS-HZFUHODCSA-N 0.000 description 2
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229940064914 retrovir Drugs 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- 229960000838 tipranavir Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NIDRYBLTWYFCFV-UHFFFAOYSA-N (-)-calanolide b Chemical compound C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
- JFKIHXVQWVFSNI-FCJVTMLMSA-N (2r,3r,4r,5r,6r,7r)-3,6-bis[(3-aminophenyl)methoxy]-2,7-dibenzyl-1,1-dioxothiepane-4,5-diol Chemical compound NC1=CC=CC(CO[C@H]2[C@H](S(=O)(=O)[C@H](CC=3C=CC=CC=3)[C@H](OCC=3C=C(N)C=CC=3)[C@H](O)[C@H]2O)CC=2C=CC=CC=2)=C1 JFKIHXVQWVFSNI-FCJVTMLMSA-N 0.000 description 1
- IXZYCIFRVZKVRJ-RKKDRKJOSA-N (2s)-n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 IXZYCIFRVZKVRJ-RKKDRKJOSA-N 0.000 description 1
- CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 description 1
- OKGPFTLYBPQBIX-CQSZACIVSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CC=NC=2NC=C1C(=O)C(=O)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 OKGPFTLYBPQBIX-CQSZACIVSA-N 0.000 description 1
- ASSJTMUEFHUKMJ-UHFFFAOYSA-N 1-acetyl-n-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(=O)N(C=1C=C(Cl)C(C)=CC=1)CCCN1CCC(CC=2C=CC(=CC=2)C(N)=O)CC1 ASSJTMUEFHUKMJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YZHIXLCGPOTQNB-UHFFFAOYSA-N 2-methyl-furan-3-carbothioic acid [4-chloro-3-(3-methyl-but-2-enyloxy)-phenyl]-amide Chemical compound C1=C(Cl)C(OCC=C(C)C)=CC(NC(=S)C2=C(OC=C2)C)=C1 YZHIXLCGPOTQNB-UHFFFAOYSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- VIBQRYBYKVEMJI-YSIASYRMSA-N 4-[[(2s,3s)-4-[(4r)-4-(tert-butylcarbamoyl)-5,5-dimethyl-1,3-thiazolidin-3-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-2,2-dimethyl-4-oxobutanoic acid Chemical compound C1SC(C)(C)[C@@H](C(=O)NC(C)(C)C)N1C(=O)[C@@H](O)[C@@H](NC(=O)CC(C)(C)C(O)=O)CC1=CC=CC=C1 VIBQRYBYKVEMJI-YSIASYRMSA-N 0.000 description 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 101150010856 CRT gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031957 HIV carrier Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- BINXAIIXOUQUKC-UIPNDDLNSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 BINXAIIXOUQUKC-UIPNDDLNSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229930184135 calanolide Natural products 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 capravirine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000007233 catalytic pyrolysis Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 235000006193 cichoric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- VDALIBWXVQVFGZ-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;chloride Chemical compound [Cl-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 VDALIBWXVQVFGZ-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 239000002835 hiv fusion inhibitor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010075606 kynostatin 272 Proteins 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229950006460 palinavir Drugs 0.000 description 1
- RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229950005820 telinavir Drugs 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000004454 trace mineral analysis Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940023080 viracept Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
SEQ ID NO: | 按5'到3'方向列出的引物序列 |
1(正向) | TCGGGTTTAT TACAGGGACt cacGtAATCC ACTTTGGAAA GGACCAGC |
2(反向) | GCTGGTCCTT TCCAAAGTGG ATTaCgtgaG TCCCTGTAAT AAACCCGA |
3(正向) | CCGAGATCTT CAGGCCCGGA GGAGGTGACA TGAGGGACAA TTG |
4(反向) | CAATTGTCCC TCATGTCACC TCCTCCGGGC CTGAAGATCT CGG |
SEQ ID NO: | 按5'到3'方向列出的引物序列 | 对扩增的有用性 |
5(正向) | ATGTCACCTCCTCCGGGC | 标签化的env基因 |
6(反向) | CAGGAATGCTTGCTGCTG | 标签化的&WT env基因 |
7(正向) | ATATCTCCTCCTCCAGGT | WT env基因 |
8(正向) | ACAGGCAACTTGGCAAATCAAA | 持家基因 |
9(反向) | TGCAGAATAAAACAAATTATAAA | 持家基因 |
10(正向) | CAGCAGTACAAATGGCAGTATTCA | 标签化的&WT整合酶编码基因 |
11(反向) | TCCTTTCCAAAGTGGATTACGTG | 标签化的整合酶编码基因 |
12(反向) | TTTCCAAAGTGGATTTCTGCTG | WT整合酶编码基因 |
SEQ ID NO: | 按5'到3'方向列出的引物序列 | 对扩增的有用性 |
19(正向) | ATTAACAAGAGATGGTGGTAA | 标签化的&WT env基因 |
20(反向) | GTGCTACTCCTAATGGTTCAA | 标签化的&WT env基因 |
24(正向) | CATTCTATCATCAACGGGTA | 人类基因组RPLPO基因 |
25(反向) | CAAAGGCAGATGGATCAG | 人类基因组RPLPO基因 |
SEQ ID NO: | 按5'到3'方向列出的底物序列 | 名称 |
17 | ATCACGCCTCguTCCTCCCAG | SubBi-6-FB |
18 | AAGGTTTCCTCguCCCTGGGCA | SubBi-2-JB |
SEQ ID NO: | 按5'到3'方向列出的底物序列 | 名称 |
17 | ATCACGCCTCguTCCTCCCAG | SubBi-6-FB |
18 | AAGGTTTCCTCguCCCTGGGCA | SubBi-2-JB |
23 | CAGCACAACCguCACCAACCG | SubBi-3-Q6B2 |
SEQ ID NO: | 按5'到3'方向列出的partzyme序列 | 名称 |
13 | ATATCTCCTCCTCCAGGTACAACGAGAGGCGTGAT-P | Partzyme A HXB2D(野生型)WTA4/6-P |
14 | CTGGGAGGAAGGCTAGCTCTGAAGATCTCGGACTCATT-P | Partzyme B HXB2D(野生型)WTB5/6-P |
15 | CTTCTCCAATTGTCCCTCATACAACGAGAGGAAACCTT-P | Partzyme A HXB2D(标签化的)TgA4/2-P |
16 | TGCCCAGGGAGGCTAGCTGTCACCTCCTCCGGG-P | Partzyme B HXB2D(标签化的)TgB5/2·P |
SEQ ID NO: | 按5'到3'方向列出的partzyme序列 | 名称 |
13 | ATATCTCCTCCTCCAGGTACAACGAGAGGCGTGAT-P | Partzyme A HXB2D(野生型)WTA4/6-P |
14 | CTGGGAGGAAGGCTAGCTCTGAAGATCTCGGACTCATT-P | Partzyme B HXB2D(野生型)WTB5/6-P |
15 | CTTCTCCAATTGTCCCTCATACAACGAGAGGAAACCTT-P | Partzyme A HXB2D(标签化的)TgA4/2-P |
16 | TGCCCAGGGAGGCTAGCTGTCACCTCCTCCGGG-P | Partzyme B HXB2D(标签化的)TgB5/2-P |
21 | CAAACGAGTCCTGGCCTTGTCTACAACGAGGTTGTGCTG-P | Partzyme A RPLPORO5A4/3-P |
22 | CGGTTGGTGAGGCTAGCTGTGGAGACGGATTACACCTTC-P | Partzyme B RPLPORO5B5/3-P |
比例Tag/WT | 标签病毒的数量(mL)(HIV HXB2D-标签化的) | WT病毒的数量(mL)(HIV HXB2D WT) |
100/0 | 2.5 | 0 |
0/100 | 0 | 2.5 |
80/20 | 2 | 0.5 |
50/50 | 1.25 | 1.25 |
20/80 | 0.5 | 2 |
对照 | 0 | 0 |
SEQ ID NO: | 按5'到3'方向列出的partzyme序列 | 名称 |
13 | ATATCTCCTCCTCCAGGTACAACGAGAGGCGTGAT-P | Partzyme A HXB2D(野生型)WTA4/6-P |
14 | CTGGGAGGAAGGCTAGCTCTGAAGATCTCGGACTCATT-P | Partzyme B HXB2D(野生型)WTB5/6-P |
15 | CTTCTCCAATTGTCCCTCATACAACGAGAGGAAACCTT-P | Partzyme A HXB2D(标签化的)TgA4/2-P |
16 | TGCCCAGGGAGGCTAGCTGTCACCTCCTCCGGG-P | Partzyme B HXB2D(标签化的)TgB5/2·P |
SEQ ID NO: | 按5'到3'方向列出的底物序列 | 名称 |
17 | ATCACGCCTCguTCCTCCCAG | SubBi-6-FB |
18 | AAGGTTTCCTCguCCCTGGGCA | SubBi-2-JB |
SEQ ID NO: | 按5'到3'方向列出的引物序列 | 名称 |
19(正向) | ATTAACAAGAGATGGTGGTAA | 5HIV |
20(反向) | GTGCTACTCCTAATGGTTCAA | 3HIV |
SEQ ID NO: | 按5'到3'方向列出的partzyme序列 | 名称 |
13 | ATATCTCCTCCTCCAGGTACAACGAGAGGCGTGAT-P | Partzyme A HXB2D(野生型)WTA4/6-P |
14 | CTGGGAGGAAGGCTAGCTCTGAAGATCTCGGACTCATT-P | Partzyme B HXB2D(野生型)WTB5/6-P |
15 | CTTCTCCAATTGTCCCTCATACAACGAGAGGAAACCTT-P | Partzyme A HXB2D(标签化的)TgA4/2·P |
16 | TGCCCAGGGAGGCTAGCTGTCACCTCCTCCGGG-P | Partzyme B HXB2D(标签化的)TgB5/2-P |
21 | CAAACGAGTCCTGGCCTTGTCTACAACG AGGTTGTGCTG-P | Partzyme A RPLPO RO5A4/3-P |
22 | CGGTTGGTGAGGCTAGCTGTGGAGACGGATTACACCTTC-P | Partzyme B RPLPO RO5B5/3-P |
SEQ ID NO: | 按5'到3'方向列出的底物序列 | 名称 |
17 | ATCACGCCTCguTCCTCCCAG | SubBi-6-FB |
18 | AAGGTTTCCTCguCCCTGGGCA | SubBi-2-JB |
23 | CAGCACAACCguCACCAACCG | SubBi-3-Q6B2 |
SEQ ID NO: | 按5'到3'方向列出的引物序列 | 名称 |
19(正向) | ATTAACAAGAGATGGTGGTAA | 5HIV |
20(反向) | GTGCTACTCCTAATGGTTCAA | 3HIV |
24(正向) | CATTCTATCATCAACGGGTA | 5RO5 |
25(反向) | CAAAGGCAGATGGATCAG | 3RO5 |
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111802.4 | 2005-12-07 | ||
EP05111802 | 2005-12-07 | ||
PCT/EP2006/069422 WO2007065926A1 (en) | 2005-12-07 | 2006-12-07 | Methods, plasmid vectors and primers for assessing hiv viral fitness |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101365808A true CN101365808A (zh) | 2009-02-11 |
CN101365808B CN101365808B (zh) | 2012-04-25 |
Family
ID=36087674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800519873A Expired - Fee Related CN101365808B (zh) | 2005-12-07 | 2006-12-07 | 用于评估hiv病毒适应度的方法、质粒载体和引物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8673551B2 (zh) |
EP (1) | EP1960554B1 (zh) |
CN (1) | CN101365808B (zh) |
AT (1) | ATE512235T1 (zh) |
AU (1) | AU2006323930B2 (zh) |
CA (1) | CA2631881C (zh) |
WO (1) | WO2007065926A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101600808A (zh) * | 2006-10-06 | 2009-12-09 | 强生研究有限公司 | 分子开关及其使用方法 |
CN105907720A (zh) * | 2016-05-11 | 2016-08-31 | 南方医科大学 | 一种hiv抑制剂筛选模型及其制备方法和应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2385141T3 (da) | 2005-10-07 | 2013-10-28 | Speedx Pty Ltd | Flerkomponentnukleinsyreenzymer og fremgangsmåder til anvendelse heraf |
EP1987166A4 (en) | 2006-02-03 | 2010-06-02 | Univ Columbia | DEOXYRIBOZYME BINARY PROBES FOR ANALYSIS OF NUCLEIC ACID |
AU2008235256B2 (en) | 2007-04-05 | 2014-05-15 | Speedx Pty Ltd | Nucleic acid enzymes and complexes and methods for their use |
CA2682337C (en) * | 2007-04-06 | 2017-01-17 | Virco Bvba | Respiratory syncytial virus (rsv) viral load detection assay |
AU2010247444A1 (en) * | 2009-05-12 | 2011-11-24 | Virco Bvba | HIV-1-C resistance monitoring |
US9051606B2 (en) | 2010-09-10 | 2015-06-09 | Qiagen Gaithersburg, Inc. | Methods and compositions for nucleic acid detection |
AU2013202354A1 (en) * | 2012-06-18 | 2014-01-16 | Speedx Pty Ltd | Target detection and signal amplification |
CN111404764B (zh) * | 2019-01-02 | 2021-11-19 | 中国移动通信有限公司研究院 | 一种电信云预集成部署测试方法及装置 |
CN113025746B (zh) * | 2019-12-09 | 2022-06-07 | 北京博奥晶典生物技术有限公司 | 利用nasba检测rev的方法及使用的成套试剂 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4000159A (en) | 1974-06-28 | 1976-12-28 | Phillips Petroleum Company | Preparation of n,n-disubstituted thioamides |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5176995A (en) | 1985-03-28 | 1993-01-05 | Hoffmann-La Roche Inc. | Detection of viruses by amplification and hybridization |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5888767A (en) * | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
CN1209875A (zh) | 1996-01-26 | 1999-03-03 | 维科公司 | 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法 |
IL138126A0 (en) | 1998-03-05 | 2001-10-31 | Johnson & Johnson Res Pty Ltd | Zymogenic nucleic acid detection methods and related molecules and kits |
GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
DE19850186A1 (de) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | Neue Primer und Sonden zum Nachweis von HIV |
AU3438999A (en) * | 1999-05-07 | 2000-11-21 | Nationales Zentrum Fur Retroviren | Detection system for human immunodeficiency virus based on nucleic acid amplification |
AU2002213882A1 (en) * | 2000-09-08 | 2002-03-22 | Biomerieux B.V.A. | Attenuated hiv strains and use thereof |
GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
EP1285971B1 (en) | 2001-08-08 | 2007-10-10 | Tibotec Pharmaceuticals Ltd. | Methods for the phenotypic and genotypic assessment of the drug sensitivity of HIV integrase variants |
EP1283272B1 (en) * | 2001-08-08 | 2013-11-13 | Janssen R&D Ireland | Methods and means for assessing HIV envelope inhibitor therapy |
US6852491B2 (en) * | 2001-09-04 | 2005-02-08 | Abbott Laboratories | Amplification and detection reagents for HIV-1 |
US7468274B2 (en) | 2004-01-30 | 2008-12-23 | The Johns Hopkins University | Single cell analysis of HIV replication capacity and drug resistance |
FR2869045A1 (fr) | 2004-04-16 | 2005-10-21 | Bioalliance Pharma Sa | Methode d'etude de la variabilite genetique et fonctionnelle du vih et kit pour sa mise en oeuvre |
ES2244332B1 (es) | 2004-05-10 | 2007-02-16 | Fundacion Para La Investigacion Y La Prevencion Del Sida En España | Nuevos clones virales recombinantes basados en vih y su utilizacion en metodos analiticos. |
DK2385141T3 (da) | 2005-10-07 | 2013-10-28 | Speedx Pty Ltd | Flerkomponentnukleinsyreenzymer og fremgangsmåder til anvendelse heraf |
-
2006
- 2006-12-07 US US12/094,708 patent/US8673551B2/en active Active
- 2006-12-07 AU AU2006323930A patent/AU2006323930B2/en not_active Ceased
- 2006-12-07 WO PCT/EP2006/069422 patent/WO2007065926A1/en active Application Filing
- 2006-12-07 CN CN2006800519873A patent/CN101365808B/zh not_active Expired - Fee Related
- 2006-12-07 CA CA2631881A patent/CA2631881C/en active Active
- 2006-12-07 EP EP06841303A patent/EP1960554B1/en active Active
- 2006-12-07 AT AT06841303T patent/ATE512235T1/de not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101600808A (zh) * | 2006-10-06 | 2009-12-09 | 强生研究有限公司 | 分子开关及其使用方法 |
CN101600808B (zh) * | 2006-10-06 | 2014-07-09 | 强生研究有限公司 | 分子开关及其使用方法 |
CN105907720A (zh) * | 2016-05-11 | 2016-08-31 | 南方医科大学 | 一种hiv抑制剂筛选模型及其制备方法和应用 |
CN105907720B (zh) * | 2016-05-11 | 2019-09-13 | 南方医科大学 | 一种hiv抑制剂筛选模型及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2007065926A1 (en) | 2007-06-14 |
AU2006323930B2 (en) | 2012-06-21 |
ATE512235T1 (de) | 2011-06-15 |
US8673551B2 (en) | 2014-03-18 |
EP1960554B1 (en) | 2011-06-08 |
CA2631881A1 (en) | 2007-06-14 |
EP1960554A1 (en) | 2008-08-27 |
CN101365808B (zh) | 2012-04-25 |
CA2631881C (en) | 2015-03-24 |
AU2006323930A1 (en) | 2007-06-14 |
US20100035229A1 (en) | 2010-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101365808A (zh) | 用于评估hiv病毒适应度的方法、质粒载体和引物 | |
US6958211B2 (en) | Methods of assessing HIV integrase inhibitor therapy | |
US9631220B2 (en) | Method for designing a drug regime for HIV-infected patients | |
Fujino et al. | A simple method for the detection of measles virus genome by loop‐mediated isothermal amplification (LAMP) | |
KR102098772B1 (ko) | 아데노바이러스(Adenovirus) subtype B와 C 그리고 아데노바이러스 subtype F와 G의 screening이 가능한 검출용 primer 및 PNA probe와 이를 이용한 아데노바이러스 Real-time multiplex PCR 검출 방법 | |
CN110106285B (zh) | 一种快速检测3型人腺病毒的含内参双重等温核酸扩增方法 | |
CN110055353B (zh) | 一种快速检测7型腺病毒的含内参双重等温核酸扩增方法 | |
US20070275372A1 (en) | Methods and reagents for molecular detection of HIV-1 groups M, N and O | |
JP2004532027A (ja) | ユニバーサルマルチ変異体検出システム | |
JPH08280389A (ja) | Hivグル−プに属するレトロウイルスおよびその用途 | |
WO2006043349A1 (ja) | インフルエンザ菌の検出方法、インフルエンザ菌検出用プライマーセット及びインフルエンザ菌検出用キット | |
US5849494A (en) | Methods for sensitive detection of reverse transcriptase | |
US20060188871A1 (en) | Detection of very virulent infectious bursal disease virus | |
KR102428504B1 (ko) | SARS-CoV-2 오미크론 변이 검출용 RT-LAMP 프라이머 세트 및 이의 용도 | |
EP1285971B1 (en) | Methods for the phenotypic and genotypic assessment of the drug sensitivity of HIV integrase variants | |
JP2023552693A (ja) | 標的遺伝子変異及びウイルスゲノムの検出システム並びにその製造及び使用の方法 | |
CN107385116B (zh) | 一种检测1型人类免疫缺陷病毒的方法及其专用成套试剂 | |
US20100009341A1 (en) | Methods and means for assessing hiv gag/protease inhibitor therapy | |
JPWO2006009260A1 (ja) | E型肝炎ウイルスの検出方法 | |
US9994886B2 (en) | Modified Epstein-Barr virus DNA polymerase and methods for isothermal DNA amplification | |
JP3351773B2 (ja) | Hiv−1のサブタイプ決定法 | |
US20070269797A9 (en) | Method for analysis of the phenotypic characteristics of the human immunodeficiency virus (HIV) | |
CN117551817A (zh) | 一种检测甲型流感病毒的靶基因、引物探针组合以及试剂盒和应用 | |
Samuel et al. | Genotyping of measles and mumps virus strains using amplification refractory mutation system analysis combined with enzyme immunoassay: a simple method for outbreak investigations | |
CN117821666A (zh) | 用于检测hiv-1的引物组及其应用和检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SEBIDICKS CO., LTD. Free format text: FORMER OWNER: JOHNSON + JOHNSON RESEARCH PTY. LIMITED Effective date: 20120227 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120227 Address after: The Irish Village Applicant after: TIBOTEC PHARMACEUTICALS Ltd. Co-applicant after: JOHNSON & JOHNSON RES Pty Ltd. Address before: The Irish Village Applicant before: TIBOTEC PHARMACEUTICALS Ltd. Co-applicant before: JOHNSON & JOHNSON RESEARCH Pty Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: IRELAND JANSSEN R + D COMPANY Free format text: FORMER OWNER: JANSSEN R + D IRELAND Effective date: 20150728 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: JANSSEN R + D IRELAND Free format text: FORMER NAME: TIBOTEC PHARM LTD. Owner name: TIBOTEC PHARM LTD. Free format text: FORMER NAME: TIBOTEC NV |
|
CP01 | Change in the name or title of a patent holder |
Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Patentee after: JOHNSON & JOHNSON RES Pty Ltd. Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Patentee before: Johnson & Johnson Res Pty Ltd. Address after: The Irish Village Patentee after: TIBOTEC PHARMACEUTICALS Patentee after: JOHNSON & JOHNSON RES Pty Ltd. Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Ltd. Patentee before: Johnson & Johnson Res Pty Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150728 Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Patentee after: JOHNSON & JOHNSON RES Pty Ltd. Address before: The Irish Village Patentee before: JANSSEN R&D IRELAND Patentee before: Johnson & Johnson Res Pty Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 |